凯盛新材(301069) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was ¥248,028,189.67, a decrease of 3.82% compared to ¥257,889,942.36 in the same period last year[5] - Net profit attributable to shareholders was ¥50,672,203.78, down 26.39% from ¥68,837,886.38 year-on-year[5] - Total operating revenue for Q1 2023 was CNY 248,028,189.67, a decrease of 3.34% compared to CNY 257,889,942.36 in Q1 2022[22] - Net profit for Q1 2023 was CNY 50,609,357.55, down 26.54% from CNY 68,837,886.38 in the same period last year[23] - The total comprehensive income for Q1 2023 was ¥50,609,357.55, down from ¥68,837,886.38 in Q1 2022[24] Cash Flow - The net cash flow from operating activities was -¥53,679,767.28, representing a decline of 109.97% compared to -¥25,565,492.63 in the previous year[5] - Cash inflow from operating activities totaled ¥96,333,280.23, a decline of 13.3% from ¥111,051,731.17 in Q1 2022[26] - Cash and cash equivalents at the end of Q1 2023 were ¥172,357,639.45, down from ¥303,024,322.61 at the end of Q1 2022, representing a decrease of 43.1%[28] - The company reported cash outflows from investing activities of ¥191,577,216.61, compared to ¥401,722,911.91 in the previous year, indicating a significant reduction in investment spending[27] - The net cash flow from investing activities was -¥16,254,776.14, contrasting with a positive cash flow of ¥128,024,770.41 in Q1 2022[27] Assets and Liabilities - Total assets at the end of the reporting period increased by 2.95% to ¥1,717,809,048.67 from ¥1,668,525,610.49 at the end of the previous year[5] - Accounts receivable rose to CNY 93,194,426.32, an increase of 25.49% from CNY 74,257,599.33 at the beginning of the year[20] - Cash and cash equivalents decreased to CNY 172,357,639.45 from CNY 242,320,450.51, a decline of 28.83%[20] - Inventory increased to CNY 54,553,932.35, up 28.43% from CNY 42,504,525.44 at the beginning of the year[20] - Total liabilities remained relatively stable at CNY 247,682,415.89, compared to CNY 247,635,312.42 at the beginning of the year[20] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 20,470, with the largest shareholder holding 44.51% of the shares[14] - Major shareholders include Huabang Life Health with 187,216,000 shares and CITIC Securities with 13,712,000 shares, all classified as pre-IPO restricted shares[17] - The total number of restricted shares at the beginning of the period was 280,200,000, with no new restrictions added during the quarter[17] - The top ten unrestricted shareholders hold a total of 18,193,600 shares, with Hongxin Guotai (Beijing) Investment Co., Ltd. being the largest[15] - The total number of unrestricted shares held by the top ten shareholders is 18,193,600, representing a significant portion of the company's equity[15] Expenses - Total operating costs increased to CNY 189,232,030.29 from CNY 178,678,210.88, reflecting a rise of 5.77%[23] - Research and development expenses increased by 53.60% to ¥1,430,000.00, reflecting the company's commitment to innovation[11] - Management expenses rose by 51.92% to ¥1,600,000.00, primarily due to increased equity incentive costs and depreciation[11] - Research and development expenses for Q1 2023 were CNY 14,307,857.49, compared to CNY 9,314,962.01 in Q1 2022, marking a 53.06% increase[23] Share Performance - The company's weighted average return on equity decreased to 3.51% from 5.26% year-on-year[5] - The basic and diluted earnings per share for Q1 2023 were both ¥0.1205, down from ¥0.1637 in the same period last year[24] Investment Income - The company experienced a 44.67% decrease in investment income, down ¥483,900.00, attributed to reduced returns from financial investments[11] - The company reported a 30.27% decrease in trading financial assets, down ¥64,726,500.00, due to reduced investment holdings to meet operational funding needs[10] Other Information - The company has not disclosed any new strategies or market expansions in the current report[18] - The company has not reported any new product developments or technological advancements in this quarter[18] - The company has no new developments or changes in the number of preferred shareholders during the quarter[16] - There are no changes in the number of restricted shares for major shareholders during the quarter[17] - The report indicates that the release date for restricted shares is set for September 27, 2024[17] - The company did not report any audited financial results for the first quarter[29]